Luxfer vs NLI
LXFR and NL side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LXFR and NL compare
Luxfer is the larger company, worth 1.3 times as much as NLI ($464M against $348M).
NLI grew revenue faster over the last twelve months (6.0% versus −11.8% for Luxfer).
Luxfer keeps more of each dollar of sales as profit, with a net margin of 1.7% compared with −15.8% at NLI.
Both pay dividends: Luxfer yields 2.2% and NLI 5.5%.
NLI scores higher on the StockData Score (13 against 11 for Luxfer), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LXFR | NL |
|---|---|---|
| Size and price | ||
| Market cap | $464M | $348M |
| Share price | $17.35 | $7.11 |
| Change, 1 year | 42.1% | 28.3% |
| Change, 5 years | −12.4% | 14.5% |
| Beta (5Y) | 0.56 | 0.53 |
| Employees | 1,350 | 549 |
| StockData Score | ||
| Total score | 11 | 13 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 2 (better) | 0 |
| Health score | 6 | 6 |
| Dividend score | 2 | 3 (better) |
| Valuation | ||
| P/E | 75.4× | – |
| P/S | 1.3× (better) | 2.1× |
| P/B | 2.1× | 1.0× (better) |
| EV/EBITDA | 22.4× | 14.0× (better) |
| P/FCF | 24.6× (better) | 42.9× |
| FCF yield | 4.1% (better) | 2.3% |
| Fair value | $8.50 | $7.67 |
| Margin of safety | −104% | 7.3% (better) |
| Growth | ||
| Revenue growth (TTM) | −11.8% | 6.0% (better) |
| Revenue growth, 5Y average | 3.4% | 6.7% (better) |
| Net income growth (TTM) | −56.6% (better) | −148% |
| EPS growth (TTM) | −56.6% (better) | −147% |
| EPS growth, 5Y average | −17.2% | – |
| Profitability | ||
| Gross margin | 25.1% | 32.1% (better) |
| Operating margin | 6.3% | 9.2% (better) |
| Net margin | 1.7% (better) | −15.8% |
| FCF margin | 5.3% (better) | 5.0% |
| Return on equity | 2.7% (better) | −6.7% |
| Return on invested capital | 5.5% (better) | 4.4% |
| Financial health | ||
| Debt / equity | 0.26 (better) | 0.00 |
| Net debt / EBITDA | 1.69 | – |
| Interest coverage | 6.6× | 122× (better) |
| Current ratio | 2.47 | 9.02 (better) |
| Altman Z-score | 3.57 | 3.92 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 2.2% | 5.5% (better) |
| Payout ratio | 221% | – |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 28.9% |
| Buyback yield | 0.56% | – |
| Shareholder yield | 2.8% | 5.5% (better) |
| Ownership | ||
| Held by institutions | 93.0% | 11.3% |
| Held by insiders | 2.0% | 0.41% |
| Insider net buying, 12 months | −$322K | – |
| Short interest, % of float | 1.7% | 0.19% |
Go deeper
- LXFR stock overview
- LXFR income statement
- LXFR valuation and score
- NL stock overview
- NL income statement
- NL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.